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Abstract
AIM: To investigate the efficacy of neoadjuvant 
chemoradiotherapy (NACRT) for resectability of locally 
advanced gastric cancer (LAGC).
METHODS: Between November 2007 and January 
2014, 29 patients with LAGC (clinically T3 with 
distal esophagus invasion/T4 or bulky regional node 
metastasis) that were treated with NACRT followed 
by D2 gastrectomy were included in this study. 
Resectability was evaluated with radiologic and 
endoscopic exams before and after NACRT. Using three-
dimensional conformal radiotherapy, patients received 
45 Gy, with a daily dose of 1.8 Gy. The entire tumor 
extent and the regional metastatic lymph nodes were 
included in the gross tumor volume. Patients presenting 
with a resectable tumor after NACRT received a total or 
subtotal gastrectomy with D2 dissection. The pathologic 
tumor response was evaluated using Japanese 
Gastric Cancer Association histologic evaluation 
criteria. Postoperative morbidity was evaluated using 
the National Cancer Institute-Common Terminology 
Criteria for Adverse Events version 4.0. Overall survival 
(OS) and progression-free survival (PFS) rates were 
estimated using a Kaplan-Meier analysis and compared 
using the log-rank test.
RESULTS: All patients were assessed as unresectable 
cases. Twenty-four patients (24/29; 82.8%) showed 
LAGC on positron emission tomography-computed 
tomography (CT) and contrast-enhanced CT, whereas 
four patients (4/29; 13.8%) with vague invasion or 
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ORIGINAL ARTICLE
Neoadjuvant chemoradiotherapy followed by D2 
gastrectomy in locally advanced gastric cancer
Retrospective Study
Mi Sun Kim, Joon Seok Lim, Woo Jin Hyung, Yong Chan Lee, Sun Young Rha, Ki Chang Keum, 
Woong Sub Koom
abutment to an adjacent organ underwent diagnostic 
laparoscopy. One patient (1/29; 3.4%), initially 
assessed as a resectable case, underwent an “open and 
closure” after the tumor was found to be unresectable. 
Abutment to an adjacent organ (34.5%) was the most 
common reason for NACRT. The clinical response rate 
one month after NACRT was 44.8%. After NACRT, 69% 
(20/29) of patients had a resectable tumor. Of the 20 
patients with a resectable tumor, 18 patients (62.1%) 
underwent a D2 gastrectomy. The R0 resection rate 
was 94.4% and two patients (2/18; 11.1%) showed a 
complete response. The median follow-up duration was 
13.5 mo. The one-year OS and PFS rates were 72.4 
and 48.9%, respectively. The one-year OS, PFS, local 
failure-free survival, and distant metastasis-free survival 
were higher in patients with a resectable tumor after 
NACRT (P < 0.001, P < 0.001, P < 0.001, and P = 0.078, 
respectively). No grade 3-4 late treatment-related 
toxicities or postoperative mortalities were observed.
CONCLUSION: NACRT with D2 gastrectomy showed 
a high rate of R0 resection and promising local control, 
which may increase the R0 resection opportunity 
resulting in survival benefit. 
Key words: Advanced gastric cancer; D2 gastrectomy; 
Neoadjuvant chemoradiotherapy; Combined modality 
therapy; Treatment outcome
© The Author(s) 2015. Published by Baishideng Publishing 
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Core tip: In locally advanced gastric cancer (LAGC), 
R0 resection is a well-established predictive factor. To 
achieve R0 resection, neoadjuvant approaches have 
been attempted. Studies of neoadjuvant chemotherapy 
followed by radical gastrectomy and D2 dissection 
have resulted in favorable outcomes and large studies 
of neoadjuvant chemotherapy are underway. Data on 
neoadjuvant chemoradiotherapy (NACRT) in LAGC are 
limited. This retrospective study was performed to 
investigate the efficacy of NACRT in LAGC. We found 
that NACRT increased the chance for an R0 resection 
and potentially enhanced survival in LAGC.
Kim MS, Lim JS, Hyung WJ, Lee YC, Rha SY, Keum KC, 
Koom WS. Neoadjuvant chemoradiotherapy followed by 
D2 gastrectomy in locally advanced gastric cancer. World J 
Gastroenterol 2015; 21(9): 2711-2718  Available from: URL: 
http://www.wjgnet.com/1007-9327/full/v21/i9/2711.htm  DOI: 
http://dx.doi.org/10.3748/wjg.v21.i9.2711
INTRODUCTION
Although the incidence of gastric cancer has decreased 
worldwide, it is still the second most common cancer 
and the third most common cause of cancer-related 
death in South Korea[1]. Even with the use of aggressive 
treatment, the five-year overall survival (OS) for 
advanced gastric cancer with adjacent organ invasion is 
< 15%[2]. To prevent recurrence and improve survival 
in gastric cancer patients, adjuvant treatments with 
radical surgery have been implemented. In European 
countries, perioperative chemotherapy is considered 
standard treatment based on the results from the 
Medical Research Council Adjuvant Gastric Infusional 
Chemotherapy (MAGIC) trial. In the United States, 
postoperative chemoradiotherapy (CRT) is considered 
standard treatment based on the Southwest Oncology 
Group 9008/Intergroup 0116 (SWOG 9008/INT 0116) 
trial[3,4]. 
Despite adjuvant treatment, the outcome of locally 
advanced gastric cancer (LAGC) remains poor[5]. 
To overcome the limitations of adjuvant treatment, 
a neoadjuvant approach has been investigated. 
In phase II clinical trials involving neoadjuvant 
chemotherapy (NAC), however, the outcomes were not 
satisfactory[6,7]. Therefore, the addition of radiotherapy 
to NAC (NACRT) was used to improve local control. In 
the Preoperative Chemotherapy or Radiochemotherapy 
in Esophagogastric Adenocarcinoma Trial (POET) 
where NACRT was compared with NAC, NACRT 
displayed a higher rate of pathologic response[8]. In 
the CRT for Oesophageal Cancer Followed by Surgery 
Study (CROSS) trial, which compared NACRT followed 
by surgery versus surgery alone, NACRT followed by 
surgery resulted in improved survival[9]. The previous 
trials, however, did not include advanced gastric 
disease, and the efficacy of NACRT in LAGC thus 
remains unclear. 
In East Asia, radical gastrectomy and D2 dissection 
(D2 gastrectomy) are considered standard surgical 
procedures. The Adjuvant Chemoradiation Therapy in 
Stomach Cancer (ARTIST) trial failed to demonstrate 
a survival benefit of adjuvant CRT in patients treated 
with a D2 gastrectomy; therefore, postoperative 
chemotherapy is currently considered the standard 
treatment[10]. Clinical trials evaluating NAC followed 
by D2 gastrectomy are underway. Nevertheless, 
conclusive data on NACRT in LAGC have not been 
established so far. The aim of the present study was to 
investigate the role of NACRT in the treatment of LAGC 
in Asian patients. We also evaluated postoperative 
morbidity following NACRT.
MATERIALS AND METHODS
Patients
We retrospectively reviewed the medical records 
of patients who were treated with NACRT between 
November 2007 and January 2014. Gastric cancer was 
histologically confirmed via endoscopic biopsy in all 
patients. Endoscopic and radiologic exams were used 
to evaluate resectability before and after NACRT. In the 
case of tumors with definite invasion or abutment to an 
adjacent organ, diagnostic laparoscopy was omitted. 
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When the invasion or abutment was vague, diagnostic 
laparoscopy was implemented. The institutional review 
board of the Yonsei University College of Medicine 
approved this study.
Treatment
The NAC regimen for each patient was determined by 
a medical oncologist. All patients underwent three-
dimensional conformal radiotherapy (RT). Gross 
tumor volume (GTV) was delineated using enhanced 
CT, positron emission tomography (PET)-CT, and 
endoscopic images. If the tumor abutted adjacent 
organs or extended to the esophagogastric junction 
or adjacent organs, the entire tumor extent was 
included in the GTV. Regional metastatic lymph nodes 
were included in the GTV. Clinical target volume was 
GTV plus a 5-10 mm margin, and the planning target 
volume was the clinical target volume plus a 7 mm 
margin. The radiation dose was 45 Gy with a daily 
dose of 1.8 Gy. The liver, kidneys, spinal cord, and 
small bowel were delineated as organs at risk. 
The standard surgical procedure was total or subtotal 
gastrectomy with D2 dissection. When resection of an 
adjacent organ was inevitable, a combined resection 
was performed. Adjuvant chemotherapy was used. If 
the tumor was unresectable after NACRT, sequential 
chemotherapy was used. 
Evaluation of response and treatment-related toxicity
After NACRT, all patients received a radiologic exam 
to assess tumor resectability and response. When 
resectability was difficult to assess using a radiologic 
approach, an endoscopic exam and diagnostic 
laparoscopy were used. The pathologic tumor response 
was evaluated using the Japanese Gastric Cancer 
Association (JGCA) histologic evaluation criteria, which 
are as follows: Grade 1a, viable tumor cells more than 
2/3 of the tumorous area; Grade 1b, viable tumor cells 
more than 1/3, but less than 2/3, of the tumorous 
area; Grade 2, viable tumor cells less than 1/3 of 
the tumorous area; Grade 3, no viable tumor cells 
remain. We evaluated treatment-related toxicity with 
the National Cancer Institute-Common Terminology 
Criteria for Adverse Events version 4.0.
Statistical analysis
The statistical methods used on this study were 
reviewed by Ha Yan Kim, a biostatistician, in Biostatistics 
Collaboration Unit, Yonsei University College of Medicine, 
Seoul, South Korea. χ2 tests and Fisher’s exact tests were 
used for comparing D2 gastrectomy group with no D2 
gastrectomy group in patient and tumor characteristics. 
OS and progression-free survival (PFS) were calculated 
using the Kaplan-Meier method and compared by using 
a log-rank test. A P < 0.05 was considered statistically 
significant. All statistical analyses were performed by 
using SPSS version 20.0 (IBM Corp., Armonk, NY, United 
States).
RESULTS
Clinical characteristics
A total of 29 patients were analyzed with a median 
age of 53 year (range: 40-74 year). All patients were 
assessed as unresectable cases. Twenty-four patients 
(24/29; 82.8%) showed LAGC on a PET-CT and 
contrast-enhanced CT prior to NACRT administration. 
Four patients (4/29; 13.8%) with vague invasion or 
abutment to an adjacent organ underwent a diagnostic 
laparoscopy. One patient (1/29; 3.4%) underwent an 
“open and closure” due to tumor infiltration into the 
perigastric area and distal esophagus. Patient data and 
tumor characteristics are summarized in Table 1. The 
2713 March 7, 2015|Volume 21|Issue 9|WJG|www.wjgnet.com
Table 1  Patient and tumor characteristics  n  (%)
Characteristics Total D2 
gastrectomy
No D2 
gastrectomy
P  value
Age (in years)   53 (40-74)   54 (42-74)   53 (40-69)    0.929
Sex    0.362
   Male 23 (79.3) 13 (72.2) 10 (90.9)
   Female   6 (20.7)   5 (27.8) 1 (9.1)
Performance status > 0.999
   ECOG 0 2 (6.9) 1 (5.6) 1 (9.1)
   ECOG 1 27 (93.1) 17 (94.4) 10 (90.9)
Tumor location    0.172
   Upper   7 (24.1)   2 (11.1) 5 (45.4)
   Mid     0 (0)       0 (0)      0 (0)
   Lower 11 (37.9)       9 (50) 2 (18.2)
   Upper-Mid   3 (10.3)   3 (16.7)      0 (0)
   Mid-Lower     0 (0)       0 (0)      0 (0)
   Upper-Lower   8 (27.6)   4 (22.2) 4 (36.4)
Pathology    0.257
   Adenocarcinoma 19 (65.5) 13 (72.2) 6 (54.5)
   Signet ring cell 
   carcinoma
  6 (20.7)   2 (11.1) 4 (36.4)
   Adeno-signet-ring 
   cell carcinoma
  4 (13.8)   3 (16.7)      1 (9.1)
Differentiation    0.619
   Well differentiated     3 (13)   2 (12.5) 1 (14.3)
   Moderately 
   differentiated
10 (43.5)   6 (37.5) 4 (57.1)
   Poorly differentiated 10 (43.5)       8 (50) 2 (28.6)
Bormann type    0.311
   1 1 (3.4)       0 (0)      1 (9.1)
   2   3 (10.3)   3 (16.7)      0 (0)
   3 22 (75.9) 13 (72.2) 9 (81.8)
   4   3 (10.3)   2 (11.1)      1 (9.1)
AJCC Clinical T stage    0.385
   T3 2 (6.9)   2 (11.1)      0 (0)
   T4a   20 (69) 11 (61.1) 9 (81.8)
   T4b   7 (24.1)   5 (27.8) 2 (18.2)
AJCC Clinical N stage    0.177
   N0   6 (20.7)   2 (11.1) 4 (36.4)
   N1   6 (20.7)   4 (22.2) 2 (18.2)
   N2 16 (55.2) 12 (66.7) 4 (36.4)
   N3a 1 (3.4)       0 (0)      1 (9.1)
AJCC Clinical Stage    0.741
   2b   5 (17.2)   2 (11.1) 3 (27.3)
   3a   3 (10.3)   2 (11.1)      1 (9.1)
   3b 18 (62.1) 12 (66.7) 6 (54.5)
   3c   3 (10.3)   2 (11.1)      1 (9.1)
AJCC: American joint committee on cancer; ECOG: Eastern cooperative 
oncology group. Results are presented as median with range in 
parentheses and number with column percentages in parentheses.
Kim MS et al . NACRT in advanced gastric cancer
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44.8%), 5-FU/cisplatin (9/29; 31%). 
Following ICT, all patients showed stable disease 
on radiologic or endoscopic exams. The first radiologic 
or endoscopic evaluation was performed within the 
first month after NACRT. The clinical response was 
as follows: 44.8% (13/29) of patients exhibited a 
partial response, 41.4% (12/29) of patients had stable 
disease, and 13.8% (4/29) of patients presented with 
progressive disease (PD). Twenty patients (20/29; 
69.0%) presented with a resectable tumor after 
NACRT (Figure 2). Of the 20 patients, four received 
ICT and NACRT and 16 received NACRT as their first 
treatment. The patients presenting with a resectable 
tumor after NACRT had similar clinical characteristics 
to those with an unresectable tumor after NACRT. 
In total, 18/29 (62%) patients underwent a D2 
gastrectomy. The median interval between NACRT 
and surgery was 2.9 mo (range: 2.1-8.0 mo). 
Seven patients (7/18; 38.9%) received a subtotal 
gastrectomy and 11 patients (11/18; 61.1%) received 
a total gastrectomy. Of the 18 patients who underwent 
surgery, 17 (94.4%) patients underwent an R0 
resection. One patient underwent an R2 resection due 
to peritoneal carcinomatosis. 
A radiologic exam revealed a single metastatic 
lesion on the liver in one patient who exhibited clinical 
PD after NACRT. The lesion was completely dissected 
by wedge resection during the gastrectomy. There 
were no viable tumor cells in the liver specimen upon 
a pathologic evaluation.
Tumor pathologic response according to the JGCA 
lower portion of the stomach was the most common 
tumor location (11/29; 37.9%). All patients had locally 
advanced disease characterized as clinically T3 with 
distal esophagus invasion/T4 or bulky regional node 
metastasis (Figure 1). The clinical T stage was from T3 
to T4b. Six patients (6/29; 15.8%) had clinically N0 
disease and 23 patients (23/29; 79.3%) had clinically 
N1-3 disease. 
NACRT was most commonly administered due to 
abutment with an adjacent organ (10/29; 34.5%), 
while invasion of an adjacent organ (8/29; 27.6%) 
was the second most common reason (Table 2). 
Treatment response and resectability after NACRT 
Of the 29 patients, six (20.7%) received induction 
chemotherapy (ICT) prior to NACRT, and 23 (79.3%) 
received NACRT as their first treatment. The ICT 
regimens were TS-1/cisplatin (33.3%) or docetaxel/
cisplatin/5-FU (66.7%). The NACRT regimen was 
heterogeneous. Approximately 76% of patients 
received cisplatin-based NACRT: TS-1/cisplatin (13/29; 
Figure 1  Computed tomography images of locally advanced gastric cancer. A: Direct tumor invasion of an adjacent organ; B: Tumor abutment with an adjacent 
organ; C: Bulky regional node metastasis; D: Invasion of the distal esophagus.
A B
C D
Cause Value
Invasion of distal esophagus   6 (20.7)
Abutment to adjacent organ 10 (34.5)
Invasion of adjacent organ   8 (27.6)
Extensive node metastasis   4 (13.8)
Other 1 (3.4)
Kim MS et al . NACRT in advanced gastric cancer
Table 2  Cause for neoadjuvant chemoradiotherapy administration 
n (%)
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histologic evaluation criteria was evaluable in 14 
patients; pathologic responses of Grade 1a, 1b, 2, and 
3 were observed in 4 (28.6%), 3 (21.4%), 5 (35.7%), 
and 2 (14.3%) patients, respectively.
After completion of NACRT, nine patients still had 
an unresectable tumor. Three patients presented with 
PD: one patient with a primary PD and two patients 
with distant metastases (DM). Although two patients 
exhibited partial response and four patients had stable 
disease, they were classified as unresectable and 
received sequential chemotherapy. Upon evaluation 
after sequential chemotherapy, one patient exhibited 
PD in the primary lesion, three patients had DM, 
and two patients had PD in the primary lesion and 
synchronous DM (Figure 2).
Survival and patterns of failure
The median follow-up duration was 13.5 mo (range: 
2.1-79.8 mo). The one-year OS of all patients was 
72.4% and the median OS was 21.2 mo. Of the 18 
patients who underwent a radical surgery, the one-
year OS was 87.7%, and the median OS was 34.3 
mo. The one-year OS of the 11 patients who did not 
receive a radical surgery was 45%, and the median OS 
was 11.5 mo (P < 0.001) (Figure 3A). 
The one-year PFS of all patients was 48.9% and 
the median time to progression was 9.9 mo. The one-
year PFS of the 18 patients who received a radical 
surgery was 68.4%, and the median PFS was 13.8 
mo. The one-year PFS of the 11 patients who did not 
receive a radical surgery was 12.8%, and the median 
PFS was 5.2 mo (P < 0.001) (Figure 3B). 
Recurrence after surgery or disease progression 
without surgery was observed in 19/29 patients (65.5%): 
two patients (6.9%) had local failure (LF) only, four 
patients (13.8%) had LF and synchronous DM, and 13 
patients (44.8%) had DM only. Peritoneal carcinomatosis 
was observed in seven patients (7/29; 24.1%). LF did 
not occur in patients who received an R0 resection, and 
the nine documented recurrences in those patients were 
DM only: lung (n = 1), liver (n = 3), liver and pancreas (n 
= 1), peritoneal carcinomatosis (n = 3), and neck node 
(n = 1). Of the 12 patients who did not receive an R0 
resection, six patients (50.0%) had LF. 
The one-year LF-free survival (LFFS) was 75.9% 
and the median time to LF has not yet been reached. 
The one-year DM-free survival (DMFS) was 57.9% 
and the median time to DM was 12.9 mo. The one-
year LFFS and DMFS of patients who underwent 
radical surgery were higher than those patients who 
did not receive radical surgery (one-year LFFS: 100% 
vs 27.3%; P < 0.001; and one-year DMFS: 68.4% vs 
33.8%; P = 0.078). The difference in DMFS, however, 
was not significant.
Treatment-related toxicity
All patients completed NACRT. Six patients (6/29; 
20.7%) presented with acute NACRT-related toxicities 
Patients with AGC (n  = 40)
Refused treatment (n  = 2)
M1 stage (n  = 9)
NACRT (n  = 29)
[ICT + NACRT (n  = 6) , NACRT (n  = 23)]
Resectable tumors (n  = 20)
[after ICT + NACRT (n  = 4), after NACRT (n  = 16)]
Refused OP (n  = 1)
F/U loss (n  = 1)
D2 gastrectomy (n  = 18)
R0 resection (n  = 17) R2 resection (n  = 1)
Unresectable tumors (n  = 9)
[after ICT + NACRT (n  = 2), after NACRT (n  = 7)]
PD (n  = 3)
     Primary PD: 1
     DM: 2
Unresectable tumor (n  = 6)
[PR (n  = 2) , SD (n  = 4)]
Sequential chemotherapy
PD (n  = 6)
     Primary PD: 1
     DM: 3
     Primary PD and DM: 2
Figure 2  Treatment flow chart. AGC: Advanced gastric cancer; DM: Distant metastasis; F/U: Follow-up; ICT: Induction chemotherapy; NACRT: Neoadjuvant 
chemoradiotherapy; OP: Operation; PD: Progressive disease; PR: Partial response; SD: Stable disease.
Kim MS et al . NACRT in advanced gastric cancer
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greater than grade 3, including leukopenia, nausea, 
anorexia, epigastric pain, and dysphagia. The grade 4 
toxicity was dizziness. The most common toxicity was 
gastrointestinal toxicity (grade 1-2: nausea, anorexia, 
epigastric pain, dysphagia). Late NACRT-related 
toxicity greater than grade 3 did not occur. 
The median postoperative hospital stay was 8 
d (range: 6-27 d). Five (27.8%) of the 18 patients 
who received radical surgery had acute postoperative 
morbidity. Most of the morbidity was grade 1. Three 
patients had grade 1 serous drainage, one patient had 
a grade 1 wound seroma, and one patient had a grade 
1 fever. One patient developed hypovolemic shock 
and pleural effusion, and recovered after hydration 
and antibiotic therapy. Seven days after surgery, the 
patient developed an abdominal abscess induced by a 
pancreatic fistula. Ten days after surgery, the patient 
presented with a wound dehiscence and underwent re-
suturing. There was no late postoperative morbidity 
or treatment-related mortality. Any treatment related 
toxicity did not cause drop out from planned surgery.
DISCUSSION
This study showed a high rate of R0 resection and 
favorable pathologic response in Asian patients with 
LAGC using NACRT followed by D2 gastrectomy. 
Patients who underwent curative surgery showed 
superior outcomes when compared to those who did 
not undergo surgery[11]. However, radical surgery 
in LAGC patients is limited due to the high risk for 
postoperative morbidity and mortality and a low rate 
of R0 resection[2]. In previous prospective studies 
of NACRT, NACRT-treated patients showed a higher 
rate of pathologic complete response and pathologic 
response when compared with NAC. Moreover, the R0 
resection rate was also higher in patients treated with 
NACRT[8,12]. R0 resection has been reported to be a 
predictive factor for survival. Klautke et al[13] reported 
a two-year survival rate of 42% in R0 resected 
patients, whereas R1 resected patients and those that 
were not operated on had a survival rate of 0%. In 
this study, 20 patients (69%) were found to have a 
resectable tumor after NACRT and the R0 resection 
rate was 94.4%. Although there is no definite standard 
for resectability at diagnosis of LAGC, all patients in 
this study had locally far advanced disease (clinically 
T3/4 and/or bulky metastatic lymph nodes), and initial 
resectability was lower than that published in previous 
studies; the R0 resection rate was comparable with 
previous studies[11,14-16]. 
The major pathologic response rate after NACRT 
was higher than that of NAC. The major pathologic 
response rate ranged from 15% to 39% in previous 
NAC studies[5-7]. In the present study, the pathologic 
response of JGCA Grade 1b and above was 71.4% and 
two patients had pathologic complete response. 
One of the main reasons for the addition of RT to 
NAC is local control. In this study, we also observed 
promising local control. A phase Ⅲ clinical trial recently 
reported on the pattern of recurrence after NACRT[12]. 
NACRT significantly reduced loco-regional recurrence 
from 34% to 14%, with only a 1% in-field recurrence. 
In a Japanese pilot study, no LF was observed after 
NACRT[17]. Other studies have also reported low LF 
and high local control rates after NACRT[11,13]. In this 
study, the one-year LFFS was 100% and no LF was 
observed during the follow-up period in the patients 
who received NACRT followed by radical surgery. 
Peritoneal carcinomatosis occurred in 24.1% of the 
patients, which is lower than previously published[18-20]. 
Inoue et al[17] explained the reason for this low rate 
of peritoneal carcinomatosis. After the tumor cells 
exposed to the peritoneum or near lymphatics were 
treated with NACRT, they underwent necrosis and were 
covered with fibrous tissue. The fibrous tissue may 
prevent the spread of tumor cells in the peritoneum. 
Therefore, patients treated with NACRT developed 
peritoneal carcinomatosis less frequently than those 
without NACRT.
DM represented the major pattern of recurrence 
in the present study. Seventeen patients (58.6%) 
had DM. To the best of our knowledge, there has not 
yet been a comparative study to determine which 
chemotherapy sequence is more effective, ICT or 
adjuvant chemotherapy. We can only suggest that 
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more intensive systemic chemotherapy is needed to 
reduce DM. The results of ongoing phase Ⅲ studies 
of NAC will provide further insight (JCOG0501; 
NCT00252161, PRODIGY; NCT01515748). 
In the current study, all patients completed NACRT 
and did not suffer from treatment-related death. 
Acute postoperative complications were manageable 
and no late postoperative morbidity or mortality was 
observed. Although surgeons are often concerned 
about postoperative morbidity and mortality following 
NACRT, a phase Ⅲ NACRT trial showed no difference 
in the rate of postoperative morbidity between the 
treatment arms, and recent NACRT studies have 
reported tolerable toxicity and safety[5,9,11,17,21].
In previous studies, grade 3-4 postoperative 
morbidity ranged from 0 to 71.4%[13,17,21-25]. Only 
one patient, who developed an abdominal abscess, 
presented with grade 3 postoperative morbidities 
(hypovolemic shock, pneumonia, wound dehiscence) 
in this study. 
Grade 3-4 postoperative mortality ranging 
from 0 to 12% has been documented in previous 
studies[13,17,21-26]. In the Japan Clinical Oncology Group 
9501 trial, which compared D2 and D3 gastrectomy, 
the mortality rate was 0.8%. In our study, all patients 
who received radical surgery underwent radical node 
dissection, but treatment-related mortality did not 
occur.
We compared clinical response after NACRT with 
the pathologic response. Out of 18 patients, 9 (50%) 
showed discordance between the clinical and pathologic 
response. Six patients had a better pathologic 
response, whereas three patients had a worse 
pathologic response when compared with the clinical 
response. One patient with clinical stable disease had 
pathologic PD (peritoneal carcinomatosis) that was 
not found on the radiologic exam prior to surgery. 
Despite improvement of radiologic imaging techniques, 
evaluations with radiologic exams have a limited 
accuracy. Leake et al[27] highlighted the substantial 
value of diagnostic laparoscopy in staging patients with 
gastric cancer, even in the era of advanced radiologic 
techniques. Trip et al[21] emphasized the need for 
accurate staging of peritoneal carcinomatosis before 
radical surgery. Both studies recommended diagnostic 
laparoscopy in LAGC patients. 
Our study had a few limitations. This was a small 
retrospective study that included heterogeneous 
chemotherapy regimens. The follow-up duration was 
relatively short compared to previous studies. In some 
patients, the resectability at diagnosis was determined 
using radiologic imaging only and a defined standard 
for resectability has not been established. Therefore, 
the initial resectability had limited accuracy.
Despite the limitations mentioned above, NACRT 
followed by D2 gastrectomy in LAGC patients showed 
a favorable pathologic response and promising 
local control. NACRT in LAGC may increase the 
opportunity for an R0 resection and, thus, for survival. 
A large prospective study of NACRT followed by D2 
gastrectomy is needed to validate the efficacy of this 
approach.
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